CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
Yi‐Hung Carol Tan(National Taiwan Normal University), Ravi Salgia(City Of Hope National Medical Center)
Cited by 105
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
|Clinical Cancer Research|2007|154
Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer
|Journal of Cellular and Molecular Medicine|2002|81